SKB336

About Klus Pharma

KLUS Pharma is a U.S.-based biotech subsidiary of China's Kelun-Biotech, leveraging its parent company's integrated R&D and manufacturing platforms to advance a diverse pipeline of oncology and non-oncology biologics. The company has built a robust pipeline with multiple clinical-stage assets, most notably in the competitive ADC space, including TROP2 and HER2-targeting candidates. Its strategy combines internal development with strategic partnerships, such as the recent collaboration with Crescent Biopharma, to maximize the global value of its pipeline. KLUS operates as a key bridge for Kelun-Biotech's ambitions in the U.S. and international markets.

Therapeutic Areas